- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05541718
New Options for Treating Knee Osteoarthritis Pain
February 5, 2024 updated by: Adam Hanley, University of Utah
This study will be a single-site, four-arm, randomized, placebo-controlled clinical trial.
Knee osteoarthritis patients (N=164) will be randomized to Reiki, Sham Reiki (placebo control), mindfulness meditation (active control), or a waitlist control condition.
The three active interventions will be applied for 20 minutes, once a week, for four consecutive weeks in a university laboratory setting.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
164
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Adam Hanley
- Phone Number: 801-213-4191
- Email: adam.hanley@utah.edu
Study Locations
-
-
Utah
-
Salt Lake City, Utah, United States, 84112
- Recruiting
- University of Utah
-
Contact:
- Adam W Hanley, PhD
- Phone Number: 801-581-6192
- Email: adam.hanley@utah.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Osteoarthritis in at least one knee
- Report a WOMAC pain score average >/= 2
- Not using any kind of energy therapy different from the proposed study
- Ability to read, understand and speak English
Exclusion Criteria:
- Knee arthroplasty in the previous year
- Have cognitive impairment as determined by clinical interview
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Waitlist Control
|
|
Active Comparator: Mindfulness Meditation
|
The mindfulness meditation intervention will be adapted from a standardized mindfulness induction script validated in prior research.
The mindfulness practice will guide patients to focus attention on breath and body sensations while monitoring and accepting discursive thoughts, negative emotions, and pain.
The MM interventionist will be a trained mindfulness provider and have experience using MM in medical settings.
|
Experimental: Reiki
|
Reiki will be provided by a trained Reiki master with the aim of balancing the flow of energy in the patient's body.
|
Sham Comparator: Sham Reiki
|
Sham Reiki will be delivered by an individual trained to simulate the Reiki interventionist's movements, but they will not visualize patient healing
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Osteoarthritis symptoms
Time Frame: One week before treatment to one week after treatment, which comprises a 6 week span
|
The Western Ontario and McMaster Universities Arthritis Index will be used to measure change in osteoarthritis symptoms.
Scores range from 0 to 96, with higher scores reflect worse pain, stiffness and physical function
|
One week before treatment to one week after treatment, which comprises a 6 week span
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Depression
Time Frame: One week before treatment to one week after treatment, which comprises a 6 week span
|
The Patient Health Questionnaire-2 will be used to measure depression.
Scores range from 0 to 6, with higher scores reflect worse depression
|
One week before treatment to one week after treatment, which comprises a 6 week span
|
Change in Anxiety
Time Frame: One week before treatment to one week after treatment, which comprises a 6 week span
|
The Generalized Anxiety Disorder 2-item will be used to measure anxiety.
Scores range from 0 to 6, with higher scores reflect worse anxiety.
|
One week before treatment to one week after treatment, which comprises a 6 week span
|
Change in Pain Catastrophizing
Time Frame: One week before treatment to one week after treatment, which comprises a 6 week span
|
The Pain Catastrophizing Scale will be used to measure pain catastrophizing.
Scores range from 0 to 52, with higher scores reflect worse pain catastrophizing
|
One week before treatment to one week after treatment, which comprises a 6 week span
|
Change in Sleep
Time Frame: One week before treatment to one week after treatment, which comprises a 6 week span
|
The PROMIS Sleep Disturbance - Short Form 6a will measure changes in sleep.
Scores range from 0 to 30, with higher scores reflect greater sleep disturbance
|
One week before treatment to one week after treatment, which comprises a 6 week span
|
Change in Quality of Life
Time Frame: One week before treatment to one week after treatment, which comprises a 6 week span
|
The WHOQOL-BREF will measure quality of life.
Scores range from 0 to 100, with higher scores reflect better quality of life
|
One week before treatment to one week after treatment, which comprises a 6 week span
|
Change in Acute Pain Intensity
Time Frame: Immediately before to after the first and last treatment session, which comprises a 20 minute span
|
Single item assessing pain intensity ("How much pain do you have?") scored on an 11-point (0=Not at all, 10=Very much) numeric rating scale.
Higher scores indicate greater pain intensity.
|
Immediately before to after the first and last treatment session, which comprises a 20 minute span
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in State Self-Transcendence
Time Frame: Immediately before to after the first and last treatment session, which comprises a 20 minute span
|
Change in self-transcendent state will be measured with the Nondual Awareness Dimensional Assessment - State Version.
Scores range from 0 to 10, with higher scores reflecting greater self-transcendence.
|
Immediately before to after the first and last treatment session, which comprises a 20 minute span
|
Change in State Decentering
Time Frame: Immediately before to after the first and last treatment session, which comprises a 20 minute span
|
Change in state decentering will be measured with the Metacognitive Processes of Decentering Scale - State Version.
Scores range from 0 to 10, with higher scores reflecting greater state decentering.
|
Immediately before to after the first and last treatment session, which comprises a 20 minute span
|
Change in Trait Self-Transcendence
Time Frame: One week before treatment to one week after treatment, which comprises a 6 week span
|
Change in trait self-transcendence will be assessed with the Nondual Awareness Dimensional Assessment - Trait Version.
Scores range from 0 to 10, with higher scores reflecting greater trait self-transcendence.
|
One week before treatment to one week after treatment, which comprises a 6 week span
|
Change in Trait Decentering
Time Frame: One week before treatment to one week after treatment, which comprises a 6 week span
|
Change in trait decentering will be assessed with the Metacognitive Processes of Decentering Scale - Trait Version.
Scores range from 0 to 10, with higher scores reflecting greater trait decentering.
|
One week before treatment to one week after treatment, which comprises a 6 week span
|
Change in Prescription Pain Medication Misuse
Time Frame: One week before treatment to one week after treatment, which comprises a 6 week span
|
The PROMIS Prescription Pain Medication Misuse v1.0 - Short Form 7a will measure prescription pain medicine misuse.
Scores range from 0 to 35, with higher scores reflecting greater misuse.
|
One week before treatment to one week after treatment, which comprises a 6 week span
|
Pleasant Sensation Ratio
Time Frame: Immediately before to after the first and last treatment session, which comprises a 20 minute span
|
Pleasant sensation ratio as measured by Sensation Manikin, a measure comprised of a visual body map to demonstrate the location and distribution of sensations.
|
Immediately before to after the first and last treatment session, which comprises a 20 minute span
|
Quantitative sensory testing
Time Frame: Immediately before the first treatment session and immediately after the last treatment session, which comprises a 4 week span
|
Pain threshold and tolerance, temporal summation, and conditioned pain modulation
|
Immediately before the first treatment session and immediately after the last treatment session, which comprises a 4 week span
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 23, 2022
Primary Completion (Estimated)
September 1, 2024
Study Completion (Estimated)
November 1, 2024
Study Registration Dates
First Submitted
September 9, 2022
First Submitted That Met QC Criteria
September 12, 2022
First Posted (Actual)
September 15, 2022
Study Record Updates
Last Update Posted (Estimated)
February 6, 2024
Last Update Submitted That Met QC Criteria
February 5, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB_00153103
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Knee Osteoarthritis
-
LifeBridge HealthMicroPort Orthopedics Inc.; Rubin Institute for Advanced OrthopedicsRecruitingKnee Osteoarthritis | Osteoarthritis, Knee | Knee Pain Chronic | Arthropathy of Knee Joint | Knee Disease | Osteoarthritis Knees Both | Osteoarthritis Knee Left | Osteoarthritis Knee RightUnited States
-
University Hospital, Clermont-FerrandSanofiCompletedKnee Osteoarthritis (Knee OA)France
-
Joseph E. BroylesCompletedDegenerative Lesion of Articular Cartilage of Knee | Degeneration; Articular Cartilage, Knee | Unilateral Primary Osteoarthritis of Knee | Osteoarthritis Knee
-
Jiangsu XinChen-Techfields Pharma Co., LTD.Completed
-
The Hong Kong Polytechnic UniversityCompleted
-
Federal University of São PauloCompletedKNEE OSTEOARTHRITISBrazil
-
Novartis PharmaceuticalsRecruitingSymptomatic Knee OsteoarthritisUnited States, Spain, Hungary, Argentina, Germany, Slovakia, Czechia, Belgium, Romania
-
University of BathUniversity of Oxford; 3D Metal Printing Ltd; Versus ArthritisRecruitingMedial Knee OsteoarthritisUnited Kingdom
-
Max Biocare Pty. Ltd.Completed
Clinical Trials on Reiki
-
University of YalovaCompleted
-
Sultan ÇEÇENCompleted
-
Mardin Artuklu UniversityCompleted
-
Ohio State UniversityCompletedMechanical Ventilation Complication | Complementary Health ApproachUnited States
-
Mayo ClinicRecruitingMultiple Myeloma | Autologous Stem Cell TransplantUnited States
-
Cukurova UniversityRecruiting
-
Mersin UniversityCompleted
-
The Cleveland ClinicNational Center for Complementary and Integrative Health (NCCIH)Completed
-
Atatürk UniversityRecruitingMultiple Sclerosis, Relapsing-RemittingTurkey
-
Hasan Kalyoncu UniversityRecruitingDiabetes Mellitus Type 2 in ObeseTurkey